# Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

> **NCT03816839** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Amcenestrant (SAR439859)

## Key facts

- **NCT ID:** NCT03816839
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-25
- **Primary completion:** 2020-10-27
- **Final completion:** 2024-12-26
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor decision to prematurely stop the study, not linked to any safety concern.
- **Last updated:** 2025-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03816839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03816839, "Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT03816839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*